Antoine FRASIE

Dr. Antoine FRASIE

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in Sensors
Verified
Journal Article
Open access
PDF file
AFAntoine FRASIE
Antoine FRASIE
HMHugo Massé-Alarie
Hugo Massé-Alarie
MBMathieu Bielmann
Mathieu Bielmann
NGNicolas Gauthier
Nicolas Gauthier
MRMourad ROUDJANE
Mourad ROUDJANE
Laurent BouyerLaurent Bouyer
Laurent Bouyer
Background: While low back pain (LBP) is the leading cause of disability worldwide, its clinical objective assessment is currently limited. Part of this syndrome arises from the abnormal sensorimotor control of back muscles, involving increased muscle fatigability (i.e., assessed with the Biering–Sorensen test) and abnormal muscle activation patterns (i.e., the flexion–extension test). Surface electromyography (sEMG) provides objective measures of muscle fatigue development (median frequency drop, MDF) and activation patterns (RMS amplitude change). This study therefore assessed the sensitivity and validity of a novel and flexible sEMG system (NSS) based on PEVA electrodes and potentially embeddable in textiles, as a tool for objective clinical LBP assessment. Methods: Twelve participants wearing NSS and a commercial laboratory sEMG system (CSS) performed two clinical tests used in LBP assessment (Biering–Sorensen and flexion–extension). Erector spinae muscle activity was recorded at T12-L1 and L4-L5. Results: NSS showed sensitivity to sEMG changes associated with fatigue development and muscle activations during flexion–extension movements (p < 0.05) that were similar to CSS (p > 0.05). Raw signals showed moderate cross-correlations (MDF: 0.60–0.68; RMS: 0.53–0.62). Adding conductive gel to the PEVA electrodes did not influence sEMG signal interpretation (p > 0.05). Conclusions: This novel sEMG system is promising for assessing electrophysiological indicators of LBP during clinical tests.

18 July 2023 in IEEE Transactions on Circuits and Systems I: Regular Papers
Verified
Journal Article
Closed access
MOMagali Ozon
Magali Ozon
AFAntoine FRASIE
Antoine FRASIE
GGGabriel Gagnon-Turcotte
Gabriel Gagnon-Turcotte
MRMourad ROUDJANE
Mourad ROUDJANE
Laurent BouyerLaurent Bouyer
Laurent Bouyer
Benoit GosselinBenoit Gosselin
Benoit Gosselin
This work presents a system for measuring and analyzing motion, by a portable electronic device and a flexible fiber sensor. The fiber is composed of multi-walled carbon nanotubes (MWCNTs) for its conductivity and polydimethylsiloxane elastomer (PDMS) for its elasticity. A new sensor interface circuit was designed in this study to interface with the fiber and measure its impedance. The measured impedance data are sampled and transmitted via Bluetooth to a laptop. The characteristics of the fiber and a wireless measurement system allow an easy integration into a smart garment to monitor various vital signs and motion markers (e.g angle, step). The system was assessed on a robotic arm before being put in realistic situations through various exercises (flexion/extension knee movements, standing multi-joint movements and walk/run on treadmill) on 5 participants for its ability to measure angle, number of movements, rate and speed. In addition, fibers measurement endurance capacities over months were observed. An assessment of the fiber impedance measurement circuit was performed (minimum resolution of 25 $\Omega$ , relative error of 2.82% on the estimated value of resistance). Tests carried out over a period of several months show that the fiber maintained good measurement performance when tested on a robotic arm, given an average correlation of 0.85 between angle and fiber impedance. The relative error (RE) made on the number of detected movements was 6.57% in average. In realistic workout situations, these values respectively reached between 0.58 and 73.95% for flexion/extension knee movements. A correlation factor of 0.76 was obtained when the participants were walking on a treadmill at a given speed. Otherwise, RE on number of movements was 8.33% for treadmill exercise, 12.84% on standing exercise. For these exercises and for the movement rate, the average correlation calculated with the reference was between 0.75 and 0.33. Finally, RE on estimated speed was 23.3% in average for the treadmill exercise. The system (sensor interface circuit and Fiber) allows to properly monitor human motion in various activities.

17 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CACharles-Antoine Auger
Charles-Antoine Auger
AFAntoine FRASIE
Antoine FRASIE
MBMaud Bouffard
Maud Bouffard
FTFrédérique Therrien
Frédérique Therrien
SBSarah Béland
Sarah Béland
LGLynn Gauthier
Lynn Gauthier
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) affects many people receiving taxane treatment for breast cancer. Symptom trajectories vary, with some recovering, and others experiencing persistent, or delayed worsening (coasting) symptoms. The prevalence and predictors of these trajectories remain unclear. This study identified the prevalence and biopsychosocial predictors of CIPN persistence, improvement, and coasting within three months post-treatment. Methods: This secondary analysis included participants treated with taxanes for stage I-III breast cancer who completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity-4 (FACT/GOG-NTX-4) at baseline, post-chemotherapy, and three months later. A minimally important difference (MID) from baseline on the FACT/GOG-NTX-4 defined persistence, improvement, coasting, and no MID-CIPN (below the MID threshold at each assessment) trajectories. Baseline assessments included self-reported pain/well-being, sensory, balance, and lower limb physical functioning measures, and sociodemographic and treatment data were collected. Results: Among 102 participants (51.57±11.24 years), persistence occurred in 34.3%, improvement in 25.5%, coasting in 6.9%, and no MID-CIPN in 33.3%. Compared to no MID-CIPN, older age (OR=1.120; 95%CI: 1.026–1.222), higher expected pain (OR=1.630; 95%CI: 1.082–2.456), and cold hyperalgesia at the foot (OR=1.130; 95%CI: 1.018–1.254) predicted persistence. Lower fatigue predicted improvement (OR=0.904; 95%CI: 0.845–0.968). No predictors were identified for coasting. Conclusion: CIPN trajectories are heterogeneous. Age and pre-treatment pain expectations, cold hyperalgesia, and fatigue differentiate patients with persistent CIPN and those likely to improve from those with no CIPN. Implications for Cancer Survivors: Early identification of individuals at risk for persistent neurotoxicity may support risk stratification and guide targeted supportive care strategies.